DGAP-News: Presse Release: 4SC hires experienced pharmaceutical manager and oncology expert

 DGAP-News: Presse Release: 4SC hires experienced pharmaceutical manager and  oncology expert  DGAP-News: 4SC AG / Key word(s): Change of Personnel Presse Release: 4SC hires experienced pharmaceutical manager and oncology expert  03.07.2014 / 07:30  ---------------------------------------------------------------------  Press release  4SC hires experienced pharmaceutical manager and oncology expert  Planegg-Martinsried, Germany, 3 July 2014 - 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, today announced that Dr Erich Enghofer has joined 4SC in June 2014 in the newly created position of Executive Vice President Oncology and Haematology thus further strengthening the company's expertise. The highly experienced pharma manager and oncology expert will primarily advance the strategic marketing of 4SC's main product resminostat in its further development toward market approval in the liver cancer indication. In this connection, Dr Enghofer will further strengthen 4SC's positioning and products vis-à-vis potential pharmaceutical partners, strategic and clinical opinion leaders and investors, and also support the company in its partnering activities in the field of business development.  Dr Enghofer has more than 30 years of experience in the pharmaceutical industry with a focus on oncology, during which he held various management and executive positions at Bayer, Medac Schering Onkologie, Amgen, Cyanamid-Lederle and Klinge Pharma (now Astellas). For the last nine years, he was head of the Business Unit Oncology (Haematology-Oncology since 2011) at Bayer HealthCare Deutschland in Leverkusen until May 2014. In this function, he was instrumental, among other things, in the attainment of market approval of the small molecule anti-cancer drug sorafenib (Nexavar(R)) in the liver cancer indication and the drug's market success in Germany. Dr Enghofer was a Board member of Deutsche Krebsgesellschaft (DKG, the German Cancer Society) until May 2014 and is a member of various high-profile professional organisations such as the German Association for Haematology and Oncology (DGHO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH) and the American Association for the Advancement of Science (AAAS).  Enno Spillner, CEO of 4SC AG, commented: "We are delighted to have Dr Erich Enghofer, an experienced pharmaceutical manager, joining 4SC. His vast expertise in the field of oncology, especially with the drug sorafenib for treating liver cancer, will further strengthen our team and is most welcome - especially for positioning our compound resminostat as a new potential liver cancer therapy and in our ongoing preparations for a Phase II trial in this indication. Dr Enghofer will also provide crucial support to 4SC in the expansion of a partner network to key opinion leaders and pharmaceutical companies, as well as in the business development process."  Dr Erich Enghofer commented: "I am very much looking forward to working in such a dynamic biotechnology company as 4SC, which has developed a promising and innovative approach for the liver cancer indication with resminostat. I have been following the company's activities and product developments, especially resminostat, for several years now. Liver cancer is the fifth most common type of cancer worldwide and the third most frequent tumour-related cause of death. The number of new cases has been rising sharply over the recent years, giving rise to a high unmet medical need. My goal is to make a contribution to attaining market approval for resminostat so as to make it available for patients as quickly as possible."  Ends  About 4SC   The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 64 employees (55 FTEs) at 31 March 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.  Cautionary statement regarding forward-looking statements  This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.  For more information please visit www.4sc.com or contact:  4SC AG  Jochen Orlowski, Corporate Communications & Investor Relations jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366  MC Services  Katja Arnold, Michelle Kremer katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840  The Trout Group  Chad Rubin  crubin(at)troutgroup.com, Tel.: +1-646-378-2947   End of Corporate News  ---------------------------------------------------------------------  03.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement.  DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de  ---------------------------------------------------------------------   Language:    English                                                 Company:     4SC AG                                                               Am Klopferspitz 19a                                                  82152 Martinsried                                                    Germany                                                 Phone:       +49 (0)89 7007 63-0                                     Fax:         +49 (0)89 7007 63-29                                    E-mail:      public@4sc.com                                          Internet:    www.4sc.de                                              ISIN:        DE0005753818                                            WKN:         575381                                                  Listed:      Regulierter Markt in Frankfurt (Prime Standard);                     Freiverkehr in Berlin, Düsseldorf, München, Stuttgart       End of News    DGAP News-Service   ---------------------------------------------------------------------   276364 03.07.2014                                                        
Press spacebar to pause and continue. Press esc to stop.